Pharmaceuticals, Biotechnology and Life Sciences
BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC), today announced that Joichi “Joi” Ito, Ph.D., has stepped down from the board of…
PureTech will continue to leverage leadership in Brain-Immune-Gut axis biology to develop novel categories of therapeutics
PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system,…
Gelesis Inc, a subsidiary of PureTech Health, has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study, to assess the long-term efficacy and safety of its Gelesis100.
PureTech Health’s subsidiary Akili announced results from a project EVO pilot study demonstrating improved cognitive control in children with sensory processing dysfunction and attentional deficits.
PureTech Health said on Friday that it will advance with Novartis two clinical-stage programmes targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.
PureTech Health has named new Chief Medical Officer to see all clinical operations across its pipeline and will focus on pushing chances that have most potential for patients.
Gelesis, focused on developing first-in-class products to safely induce weight loss and improve glycaemic control, has presented new data for its second product candidate, Gelesis200
The study, which will be conducted in up to 70 healthy individuals, aims to evaluate the tolerability of KarXT compared to xanomeline alone.